Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer

Current Colorectal Cancer Reports

Volumn 5, Issue 3, 2009, Pages 151-157

  Vergo, Max ^a   Nimeiri, Halla ^a   Benson III, Al B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLON CANCER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; HUMAN; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; RECTUM CARCINOMA; RECTUM RESECTION; REVIEW; SURVIVAL TIME;

EID: 77954959616     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-009-0022-9     Document Type: Review

References (39)

1. Fisher B, Wolmark N, Rockette H, et al.: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988, 80:21-29. (Pubitemid 18076565)
2. Heald RJ, Moran BJ, Ryall RD, et al.: Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998, 133:894-899.
3. Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg 1982, 69:613-616. (Pubitemid 12038080)
4. MacFarlane JK, Ryall RD, Heald RJ: Mesorectal excision for rectal cancer. Lancet 1993, 341:457-460. (Pubitemid 23054519)
5. Enker WE, Thaler HT, Cranor ML, Polyak T: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995, 181:335-346.
6. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997, 336:980-987. [Published erratum appears in N Engl J Med 1997, 336:1539.]
7. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
8. Gerard JP, Conroy T, Bonnetain F, et al.: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625. (Pubitemid 46630960)
9. Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
10. Bosset JF, Collette L, Calais G, et al.: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123. [Published erratum appears in N Engl J Med 2007, 357:1114-1123.] The seminal, prospective, randomized trial EORTC 22921 evaluated the benefit of adding adjuvant chemotherapy after neoadjuvant chemoradiation in clinical T3/T4 resectable rectal cancer and found only a trend toward improvement in OS with adjuvant chemotherapy.
11. Collette L, Bosset JF, den Dulk M, et al.: Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25:4379-4386. Retrospective analysis of the EORTC 22921 trial showed improvement in 5-year disease-free survival and OS in patients experiencing tumor downstaging to pathologic T0-2 after neoadjuvant chemoradiation.
12. Janjan NA, Crane C, Feig BW, et al.: Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001, 24:107-112. (Pubitemid 32323343)
13. Das P, Skibber JM, Rodriguez-Bigas MA, et al.: Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 2006, 29:219-224. A large M.D. Anderson retrospective review of their experience with chemoradiation in rectal cancer showed that pathologic tumor and nodal stage are important factors for predicting local recurrence, relapse from distant metastases, and OS. Most patients received adjuvant chemotherapy.
14. Chan AK, Wong AO, Langevin J, et al.: Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys 2000, 48:843-856.
15. Fietkau R, Barten M, Klautke G, et al.: Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006, 49:1284-1292. (Pubitemid 44401376)
16. Saw RP, Morgan M, Koorey D, et al.: p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 2003, 46:192-202. (Pubitemid 36222619)
17. Jernvall P, Makinen MJ, Karttunen TJ, et al.: Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999, 79:903-908. (Pubitemid 29082124)
18. Guerra A, Borda F, Javier Jimenez F, et al.: Multivariate analysis of prognostic factors in resected colorectal cancer: a new prognostic index. Eur J Gastroenterol Hepatol 1998, 10:51-58. (Pubitemid 28085500)
19. Colombino M, Cossu A, Manca A, et al.: Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. Ann Oncol 2002, 13:1447-1453.
20. Uen YH, Lin SR, Wu DC, et al.: Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg 2007, 246:1040-1046.
21. Johnston PG, Fisher ER, Rockette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12:2640-2647. (Pubitemid 24379651)
22. Ghadimi BM, Grade M, Difilippantonio MJ, et al.: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005, 23:1826-1838. (Pubitemid 46217459)
23. Swain SM, Lippman ME, Egan EF, et al.: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989, 7:890-899. (Pubitemid 19172462)
24. Danenberg PV: Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977, 473:73-92.
25. Santi DV, McHenry CS, Sommer M: Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471-480.
26. Santi DV, Danenberg PV: Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridylate folates in pyrimidine nucleotide biosynthesis. In Folates and Pterins. Edited by Blakely RL, Benkovic SJ. New York: Wiley; 1984:385-398.
27. Berger SH, Jenh CH, Johnson LF, Berger FG: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine- resistant human cells. Mol Pharmacol 1985, 28:461-467. (Pubitemid 16224251)
28. Clark JL, Berger SH, Mittelman A, Berger FG: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 1987, 71:261-265. (Pubitemid 17051726)
29. Spears CP, Shahinian AH, Moran RG, et al.: In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982, 42:450-456. (Pubitemid 12173578)
30. Washtein WL: Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil. Mol Pharmacol 1984, 25:171-177.
31. Johnston PG, Drake JC, Trepel J, Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992, 52:4306-4312.
32. Chu E, Koeller DM, Johnston PG, et al.: Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993, 43:527-533. (Pubitemid 23112729)
33. Liersch T, Langer C, Ghadimi BM, et al.: Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 2006, 24:4062-4068. Patients from the CAO/ARO/AIO-94 trial who had higher levels of intratumoral TS expression after neoadjuvant therapy were found to have higher rates of disease recurrence.
34. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. (Pubitemid 38702845)
35. Freyer G, Bossard N, Romestaing P, et al.: Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 2001, 19:2433-2438. (Pubitemid 32391214)
36. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al.: A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 2005, 93:993-998. (Pubitemid 41548392)
37. Aschele C, Friso ML, Pucciarelli S, et al.: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005, 16:1140-1146. (Pubitemid 41418317)
38. Ryan DP, Niedzwiecki D, Hollis D, et al.: Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006, 24:2557-2562. (Pubitemid 46630634)
39. Minsky BD: Adjuvant management of rectal cancer: the more we learn, the less we know. J Clin Oncol 2007, 25:4339-4340.